ABUS vs GEN · P/E 5.4, rev $6.2M vs P/E 17, rev $5.00B
Arbutus Biopharma Corp (ABUS) versus Gen Digital Inc. (GEN) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Gen Digital Inc. (GEN) is a software - infrastructure company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported GEN revenue for 2026-04-03 was $5.00B. Net income was $973.0M. Revenue was up 27.1% from 2025-03-28 to 2026-04-03. GEN currently screens at market cap $15.83B and trailing P/E 16.7.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. GEN currently screens at market cap $15.83B and trailing P/E 16.7.
Not investment advice. Open the ABUS and GEN stock pages for the full models.
Not investment advice.